Outlook Therapeutics (OTLK) Capital Leases (2015 - 2022)
Outlook Therapeutics (OTLK) posted quarterly Capital Leases of $1084.0 for Q4 2022, down 91.8% year-over-year from $13221.0 in Q4 2021, and down 74.6% quarter-over-quarter from $4267.0 in Q3 2022.
Outlook Therapeutics (OTLK) Capital Leases (2015 - 2022) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Capital Leases for 8 consecutive years, with $1084.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Capital Leases fell 91.8% year-over-year to $1084.0; the TTM figure through Dec 2022 stood at $1084.0 (down 91.8% YoY), while the FY2022 annual figure was $4267.0, down 73.36% from the prior year.
- Capital Leases retreated to $1084.0 in Q4 2022 per OTLK's latest filing, from $4267.0 in the prior quarter.
- Across five years, Capital Leases topped out at $3.5 million in Q1 2018 and bottomed at $1084.0 in Q4 2022.
- Historically, Capital Leases has averaged $1.5 million across 5 years, with a median of $45822.0 in 2020.
- Annual changes were most pronounced in 2018 — Capital Leases surged 12203.62% — and 2021, when it slumped 99.14%.
- Outlook Therapeutics' Capital Leases stood at $3.4 million in 2018, then retreated by 1.64% to $3.3 million in 2019, then plunged by 98.93% to $35682.0 in 2020, then plunged by 62.95% to $13221.0 in 2021, then slumped by 91.8% to $1084.0 in 2022.
- Business Quant data shows OTLK's Capital Leases at $1084.0 in Q4 2022, $4267.0 in Q3 2022, and $7349.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1,084.00 |
| Sep 30, 2022 | 4,267.00 |
| Jun 30, 2022 | 7,349.00 |
| Mar 31, 2022 | 10,332.00 |
| Dec 31, 2021 | 13,221.00 |
| Sep 30, 2021 | 16,018.00 |
| Jun 30, 2021 | 21,703.00 |
| Mar 31, 2021 | 28,755.00 |
| Dec 31, 2020 | 35,682.00 |
| Sep 30, 2020 | 42,482.00 |
| Jun 30, 2020 | 49,162.00 |
| Mar 31, 2020 | 3.35 Mn |
| Dec 31, 2019 | 3.34 Mn |
| Sep 30, 2019 | 3.37 Mn |
| Jun 30, 2019 | 3.35 Mn |
| Mar 31, 2019 | 3.39 Mn |
| Dec 31, 2018 | 3.40 Mn |
| Sep 30, 2018 | 3.45 Mn |
| Jun 30, 2018 | 3.51 Mn |
| Mar 31, 2018 | 3.51 Mn |